We are dedicated to making a difference by transforming patient experiences. Our clinical trials have been and may continue to be affected by the COVID-19 pandemic. The trial was originally designed to include 128 subjects. We released topline results from the UFL Trial in December of 2020. DaxibotulinumtoxinA for Injection was well-tolerated at all dose levels. In February 2021, we announced topline data from the JUNIPER Phase 2 trial. On May 2, 2019 our European Patent No. We are vigorously defending this patent in the European Patent Office. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Other states in the United States are also beginning to propose laws similar to the CCPA. In many jurisdictions, enforcement actions and consequences for noncompliance are rising. Cyberattacks and other malicious internet-based activity continue to increase. In addition, we have had to put in place a work from home policy for all employees. Teoxane must do the same with its PMAs to the FDA for the RHA® Pipeline Products. We do not have control over Teoxane's compliance with these regulations and standards. The amount and timing of these possible charges are not yet known. Leadership transitions can be inherently difficult to manage. A breach of confidentiality could significantly affect our competitive position. This can be expensive, particularly for a company of our size, and time-consuming. We may fail to report adverse events we become aware of within the prescribed timeframe.